Freeline Therapeutics Holdings plc acquired SwanBio Therapeutics, Inc. from Mass General Brigham Ventures, LLC, Syncona Investment Management Limited and Syncona Partners LLP on June 17, 2024. The Spur Therapeutics will be led by Freeline Chief executive officer Michael Parini and will benefit from the world-class leadership of the broader Freeline management team, who are now focused on driving forward two potentially first-in-class gene therapy assets towards late-stage development and advancing a research strategy to move gene therapy into more prevalent diseases. As part of the transaction, SwanBio Executive Chair and Syncona Executive Partner John Tsai will join the Board of Spur. The acquisition creates a new company, Spur Therapeutics (Spur), and combines two of Syncona's clinical-stage portfolio companies, representing a significant opportunity to deliver two first-in-class gene therapies and advance a pipeline targeting more prevalent chronic debilitating diseases. Syncona will own 99% of the combined SwanBio Therapeutics and Freeline Therapeutics. The acquisition has taken place at the portfolio companies' holding valuations, resulting in a combined valuation of approximately £104.7 million. Alongside the acquisition, Syncona has committed a further £40 million in financing for the company to support the development of its expanded pipeline.

Freeline Therapeutics Holdings plc completed the acquisition of SwanBio Therapeutics, Inc. from Mass General Brigham Ventures, LLC, Syncona Investment Management Limited and Syncona Partners LLP on June 17, 2024.